TEVA 57.80 Teva Pharmaceutical Industries Ltd $TEVA Hit a 52 week high of 58.03 Closing the day 11/03/14 at 57.80 +1.33 +2.36% With a day low of 55.67 and a total volume of 8,213,970.
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Upgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Mon Nov 03, 8:00AM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) was upgraded from Sector Perform to Outperform at RBC Capital today. The stock closed yesterday at $56.47 on volume of 7.8 million shares, above average daily volume of 4.1 million. Teva Pharmaceutical Industries has overhead space with shares priced $56.47, or 7.4% below the average consensus analyst price target of $60.96. The stock should find initial support at its 50-day moving average (MA) of $52.68 and further support at its 200-day MA of $50.96.
TEVA: 57.80 (+1.33)
BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen(R) for the Treatment of the Dry Form of Age-Related Macular Degeneration
Business Wire - Mon Nov 03, 6:00AM CST
--No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
BTX: 3.42 (+0.03), TEVA: 57.80 (+1.33)
Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.04 (+0.07), ACT: 247.50 (+4.76), MYL: 53.59 (+0.04), TEVA: 57.80 (+1.33)
Teva Pharmaceutical (TEVA) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 11:10AM CDT
The following Teva Pharmaceutical (TEVA) conference call took place on October 30, 2014, 08:00 AM ET. This is a transcript of that earnings call:
TEVA: 57.80 (+1.33)
Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.59 (+0.04), TEVA: 57.80 (+1.33)
Teva ups full-year EPS outlook
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Multiple sclerosis drug Copaxone boosted Teva Pharmaceutical Industries' (TEVA) Q3, as earnings rose 3.9% to $1.32, topping views for $1.24. But revenue dipped 0.02% to $5.06 bil, missing views for $5.1 bil. The company narrowed its full-year EPS...
TEVA: 57.80 (+1.33)
Watch for Teva Pharmaceutical Industries to Potentially Pullback After Gaining 3.63% Yesterday
Comtex SmarTrend(R) - Thu Oct 30, 3:42PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.80 (+1.33)
SmarTrend Watching for Potential Pullback in Shares of Teva Pharmaceutical Industries After 3.63% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:41PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.80 (+1.33)
Dow Surges 221 Points on GDP Data, Visa Earnings After Fed’s QE End
at The Street - Thu Oct 30, 3:18PM CDT
U.S. stock markets closed far higher on Thursday as the Commerce Department said U.S. gross domestic product rose 3.5% in the third quarter.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.33 (+0.09), TEVA: 57.80 (+1.33)
Stock Market Today: Visa, MasterCard Push Markets Up as Investors Digest 3.5% GDP Growth
at The Street - Thu Oct 30, 2:28PM CDT
While it brought the year’s biggest surge in volatility, October may represent a turning point for U.S. markets.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
Stock Market Today: Stocks Move Higher on Visa Earnings, 3.5% GDP Growth
at The Street - Thu Oct 30, 10:59AM CDT
U.S. stocks trade mixed after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
Stock Market Today: Futures Fall as U.S. Economy Grows 3.5% and Fed Ends QE
at The Street - Thu Oct 30, 8:07AM CDT
U.S. stock futures are trading lower after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
Teva Reports Third Quarter 2014 Results
Business Wire - Thu Oct 30, 6:04AM CDT
--Non-GAAP operating income of $1.5 billion, an increase of 13% from the third quarter of 2013. GAAP operating income of $1.1 billion, up 39%.
TEVA: 57.80 (+1.33)
Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 4:20PM CDT
Teva (TEVA) is scheduled to report third-quarter 2014 results before the opening bell on Oct 30.
TEVA: 57.80 (+1.33), AMAG: 33.82 (+0.81), BMY: 57.80 (-0.39)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.97 (+0.91), TEVA: 57.80 (+1.33), AMAG: 33.82 (+0.81), ABBV: 63.25 (-0.21)
Global Panic Disorders Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gm823g/panic_disorders) has announced the addition of the "Panic Disorders Global Clinical Trials Review, H2, 2014" report to their offering. Panic Disorders Global Clinical Trials Review, H2, 2014" provides data on the Panic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Panic Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Panic Disorders. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - GlaxoSmithKline plc - ZonMw - Bluefish Pharmaceuticals AB - Teva Pharmaceutical Industries Limited - Alexza Pharmaceuticals, Inc. - Actavis plc - Abiogen Pharma S.p.A. Clinical Trial Overview of Top Institutes / Government - National Institute of Mental Health - Massachusetts General Hospital - The University of New South Wales - Charite - Universitatsmedizin Berlin - University of Pittsburgh - Samsung Medical Center - Maastricht University Medical Center - Karolinska Institute - Federal University of Rio de Janeiro - Maastricht University For more information visit http://www.researchandmarkets.com/research/gm..._disorders
PFE: 30.19 (+0.24), TEVA: 57.80 (+1.33), GSK: 45.49 (unch), ALXA: 2.10 (-0.16)
Global Sciatica Clinical Trials Therapeutics Review, H2, 2014
M2 - Tue Oct 28, 4:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sqc7s8/sciatica_global) has announced the addition of the "Sciatica Global Clinical Trials Review, H2, 2014" report to their offering. Sciatica Global Clinical Trials Review, H2, 2014" provides data on the Sciatica clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sciatica. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sciatica. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Sciatica Therapeutics Clinical Trials - Teva Pharmaceutical Industries Limited - Medtronic, Inc. - Johnson & Johnson - Dompe Farmaceutici S.p.A. - Biogen Idec Inc. - Leiden University Medical Center - Nantes University Hospital - Ziv Medical Center - Hadassah Medical Organization - University of California, San Diego - U.S. Department of Veterans Affairs - Duke University - University Hospital, Grenoble - Johns Hopkins University - Assistance Publique - Hopitaux de Paris For more information visit http://www.researchandmarkets.com/research/sq...ica_global
JNJ: 107.46 (-0.32), BIIB: 321.25 (+0.17), MDT: 68.15 (-0.01), TEVA: 57.80 (+1.33)
Lannett Co. Gets Growth Rx In Generic Drugs Group
at Investor's Business Daily - Mon Oct 27, 4:59PM CDT
Generic-drug maker Lannett Co. boasts a robust pipeline and has its sights on growing revenue substantially over the next several years. The Philadelphia-based company is already on solid footing. In late August, it reported fiscal 2014...
LCI: 57.52 (+0.80), PRGO: 159.95 (-1.50), ACT: 247.50 (+4.76), AKRX: 43.82 (-0.73), TEVA: 57.80 (+1.33)
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Upgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Mon Nov 03, 8:00AM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) was upgraded from Sector Perform to Outperform at RBC Capital today. The stock closed yesterday at $56.47 on volume of 7.8 million shares, above average daily volume of 4.1 million. Teva Pharmaceutical Industries has overhead space with shares priced $56.47, or 7.4% below the average consensus analyst price target of $60.96. The stock should find initial support at its 50-day moving average (MA) of $52.68 and further support at its 200-day MA of $50.96.
TEVA: 57.80 (+1.33)
BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen(R) for the Treatment of the Dry Form of Age-Related Macular Degeneration
Business Wire - Mon Nov 03, 6:00AM CST
--No approved therapy exists for dry-AMD, the leading cause of visual impairment in an aging population in the US and other developed countries
BTX: 3.42 (+0.03), TEVA: 57.80 (+1.33)
Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.04 (+0.07), ACT: 247.50 (+4.76), MYL: 53.59 (+0.04), TEVA: 57.80 (+1.33)
Teva Pharmaceutical (TEVA) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 11:10AM CDT
The following Teva Pharmaceutical (TEVA) conference call took place on October 30, 2014, 08:00 AM ET. This is a transcript of that earnings call:
TEVA: 57.80 (+1.33)
Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.59 (+0.04), TEVA: 57.80 (+1.33)
Teva ups full-year EPS outlook
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Multiple sclerosis drug Copaxone boosted Teva Pharmaceutical Industries' (TEVA) Q3, as earnings rose 3.9% to $1.32, topping views for $1.24. But revenue dipped 0.02% to $5.06 bil, missing views for $5.1 bil. The company narrowed its full-year EPS...
TEVA: 57.80 (+1.33)
Watch for Teva Pharmaceutical Industries to Potentially Pullback After Gaining 3.63% Yesterday
Comtex SmarTrend(R) - Thu Oct 30, 3:42PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.80 (+1.33)
SmarTrend Watching for Potential Pullback in Shares of Teva Pharmaceutical Industries After 3.63% Gain
Comtex SmarTrend(R) - Thu Oct 30, 3:41PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $53.89 to a high of $56.66. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $55.48 on volume of 7.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.80 (+1.33)
Dow Surges 221 Points on GDP Data, Visa Earnings After Fed’s QE End
at The Street - Thu Oct 30, 3:18PM CDT
U.S. stock markets closed far higher on Thursday as the Commerce Department said U.S. gross domestic product rose 3.5% in the third quarter.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.33 (+0.09), TEVA: 57.80 (+1.33)
Stock Market Today: Visa, MasterCard Push Markets Up as Investors Digest 3.5% GDP Growth
at The Street - Thu Oct 30, 2:28PM CDT
While it brought the year’s biggest surge in volatility, October may represent a turning point for U.S. markets.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
Stock Market Today: Stocks Move Higher on Visa Earnings, 3.5% GDP Growth
at The Street - Thu Oct 30, 10:59AM CDT
U.S. stocks trade mixed after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
Stock Market Today: Futures Fall as U.S. Economy Grows 3.5% and Fed Ends QE
at The Street - Thu Oct 30, 8:07AM CDT
U.S. stock futures are trading lower after a report from the Commerce Department shows gross domestic product grew 3.5% in the third quarter, beating economists' estimates.
GPRO: 84.32 (+7.22), COP: 70.56 (-1.59), DWA: 22.04 (-0.24), SBUX: 76.10 (+0.54), RDS.A: 70.03 (-1.76), V: 241.54 (+0.11), LNKD: 233.08 (+4.12), TEVA: 57.80 (+1.33), AAPL: 109.40 (+1.40), MA: 84.13 (+0.38)
Teva Reports Third Quarter 2014 Results
Business Wire - Thu Oct 30, 6:04AM CDT
--Non-GAAP operating income of $1.5 billion, an increase of 13% from the third quarter of 2013. GAAP operating income of $1.1 billion, up 39%.
TEVA: 57.80 (+1.33)
Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 4:20PM CDT
Teva (TEVA) is scheduled to report third-quarter 2014 results before the opening bell on Oct 30.
TEVA: 57.80 (+1.33), AMAG: 33.82 (+0.81), BMY: 57.80 (-0.39)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 67.97 (+0.91), TEVA: 57.80 (+1.33), AMAG: 33.82 (+0.81), ABBV: 63.25 (-0.21)
Global Panic Disorders Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gm823g/panic_disorders) has announced the addition of the "Panic Disorders Global Clinical Trials Review, H2, 2014" report to their offering. Panic Disorders Global Clinical Trials Review, H2, 2014" provides data on the Panic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Panic Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Panic Disorders. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - GlaxoSmithKline plc - ZonMw - Bluefish Pharmaceuticals AB - Teva Pharmaceutical Industries Limited - Alexza Pharmaceuticals, Inc. - Actavis plc - Abiogen Pharma S.p.A. Clinical Trial Overview of Top Institutes / Government - National Institute of Mental Health - Massachusetts General Hospital - The University of New South Wales - Charite - Universitatsmedizin Berlin - University of Pittsburgh - Samsung Medical Center - Maastricht University Medical Center - Karolinska Institute - Federal University of Rio de Janeiro - Maastricht University For more information visit http://www.researchandmarkets.com/research/gm..._disorders
PFE: 30.19 (+0.24), TEVA: 57.80 (+1.33), GSK: 45.49 (unch), ALXA: 2.10 (-0.16)
Global Sciatica Clinical Trials Therapeutics Review, H2, 2014
M2 - Tue Oct 28, 4:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sqc7s8/sciatica_global) has announced the addition of the "Sciatica Global Clinical Trials Review, H2, 2014" report to their offering. Sciatica Global Clinical Trials Review, H2, 2014" provides data on the Sciatica clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sciatica. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sciatica. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Sciatica Therapeutics Clinical Trials - Teva Pharmaceutical Industries Limited - Medtronic, Inc. - Johnson & Johnson - Dompe Farmaceutici S.p.A. - Biogen Idec Inc. - Leiden University Medical Center - Nantes University Hospital - Ziv Medical Center - Hadassah Medical Organization - University of California, San Diego - U.S. Department of Veterans Affairs - Duke University - University Hospital, Grenoble - Johns Hopkins University - Assistance Publique - Hopitaux de Paris For more information visit http://www.researchandmarkets.com/research/sq...ica_global
JNJ: 107.46 (-0.32), BIIB: 321.25 (+0.17), MDT: 68.15 (-0.01), TEVA: 57.80 (+1.33)
Lannett Co. Gets Growth Rx In Generic Drugs Group
at Investor's Business Daily - Mon Oct 27, 4:59PM CDT
Generic-drug maker Lannett Co. boasts a robust pipeline and has its sights on growing revenue substantially over the next several years. The Philadelphia-based company is already on solid footing. In late August, it reported fiscal 2014...
LCI: 57.52 (+0.80), PRGO: 159.95 (-1.50), ACT: 247.50 (+4.76), AKRX: 43.82 (-0.73), TEVA: 57.80 (+1.33)
